Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)

<Previous Article In Volume
Next Article In Volume>

Mortality Rate of People Living with HIV/AIDS on Injection Drug Users (IDU) Compared to Non-Injection Drug Users (non-IDU)

Authors
Ni Pt Wr Pradnya Nirmala Putri1, Jaini Rahma1, Nabila Aisyah Putri1, Putu Wika Pramesti Iswari1, Salsabila Chauna1, Wina Arsylia Fakar1, Cut Warnaini2, *
1Faculty of Medicine, University of Mataram, Mataram, Indonesia
2Department of Public Health, University of Mataram, Mataram, Indonesia
*Corresponding author. Email: cut.warnaini@unram.ac.id
Corresponding Author
Cut Warnaini
Available Online 21 February 2022.
DOI
10.2991/ahsr.k.220206.048How to use a DOI?
Keywords
HIV/AIDS; transmission; mortality; injection; drug user; IDU; non-IDU
Abstract

Risk factors for transmission of HIV/AIDS are heterosexual (84.7%), Injection Drugs User (IDU) (5.7%), homosexual (4.7%), perinatal transmission (4.6%) and blood transfusion (0.1%). As the second-largest risk factor, IDU is a serious public health concern because of its high potential in transmitting HIV. The transmission of HIV in the IDU group with the unhygienic use of syringes is mostly related to hepatitis infection. On the other hand, the transmission of HIV in non-IDU is due to substance abuse, inconsistent condom use, sex work, and promiscuity. The aim of this review is to differentiate the mortality rates on IDU and non-IDU. Our search strategy was carried out by looking through scientific articles published from 2010 to 2021 from PubMed, Google Scholar, and non-peer-reviewed literature. We obtained 25 articles, but only 7 articles are considered relevant. Our findings indicate that the IDU group has a 50% higher mortality rate than non-IDU due to HIV-related complications and co-morbidities such as Hepatitis C. The comparison of survival between IDU and non-IDU for IDU is 53.2% [95% CI: 48.1-58.3], and non-IDU is 82,1% (95% CI: 80.7-83.6) respectively. Indeed, at the time of HIV diagnosis, higher CD4+ counts were present in the IDU group (IDU: median 358 cells/ml, IQR (200–561 cells/ml); non-IDU: median 300 cells/ml, IQR (130–486 cells/ml; P=0.0003). Therefore, our finding suggests that mortality rate in the IDU group is relatively higher compared to non-IDU.

Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
Series
Advances in Health Sciences Research
Publication Date
21 February 2022
ISBN
978-94-6239-540-4
ISSN
2468-5739
DOI
10.2991/ahsr.k.220206.048How to use a DOI?
Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

risenwbib
TY  - CONF
AU  - Ni Pt Wr Pradnya Nirmala Putri
AU  - Jaini Rahma
AU  - Nabila Aisyah Putri
AU  - Putu Wika Pramesti Iswari
AU  - Salsabila Chauna
AU  - Wina Arsylia Fakar
AU  - Cut Warnaini
PY  - 2022
DA  - 2022/02/21
TI  - Mortality Rate of People Living with HIV/AIDS on Injection Drug Users (IDU) Compared to Non-Injection Drug Users (non-IDU)
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 257
EP  - 264
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.048
DO  - 10.2991/ahsr.k.220206.048
ID  - Putri2022
ER  -